People
With the end of June, numerous biotechs shored up their boards of directors and other advisory boards with new members as the companies continued to shape their future strategies.
A recent change to the definition of “smaller reporting company” by the U.S. Securities and Exchange Commission earned praise from the Biotechnology Innovation Organization.
The senior leadership team at Israel-based BrainStorm Cell Therapeutics, Inc. has changed with the appointments of two seasoned industry veterans Joseph Petroziello and Susan Ward.
A group of Takeda Pharmaceutical shareholders’ bid to halt the acquisition of Dublin-based Shire failed to gain traction.
Nearly four years after first forging a research collaboration, AbbVie and Calico, Google’s life science company, have extended that 10-year pact with another $1 billion pledge to develop therapies associated with age-related diseases, including neurodegeneration and cancer.
Roivant Sciences, Vivek Ramaswamy’s umbrella company for his family of “Vants,” announced major restructuring that includes a cut of 10 percent of staff and reshuffling of leadership.
The week of June 18 to June 22 was bookended by a big hiring announcement in the pharma industry. It began with a former Cowen analyst being tapped as chief financial officer of startup Allogene and ended with the retirement announcement of the group worldwide chairman at Johnson & Johnson.
There is another change coming to the senior leadership team at Swiss pharma giant Roche.
As a female chief executive officer in the healthcare industry Karen Zaderej often stands out in a male-dominated industry.
Sunny Balwani intends to fight not only the criminal charges, but is also fighting the charges brought by the SEC.
PRESS RELEASES